Analyst Ratings for Acadia Pharmaceuticals (ACAD)
ACAD Rating Summary
ACAD Price Target Summary
- Highest: $37.00 (TD Cowen)
- Lowest: $14.50 (BofA Securities)
- Average: $29.98
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$29.98 (+56.8%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 58%
Avg. $ Target:
$29.98 (+56.8%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 58%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/13/2026 | UBS | Ashwani Verma | Downgrade | Neutral (Buy) |
23.00 (49.00) |
19.41 (19.12) |
-1.49% | Details |
| 3/25/2026 | BofA Securities » Updated 7/29/2026 |
Tazeen Ahmad | Upgrade | Buy (Neutral) |
14.50 (13.00) |
20.96 (19.12) |
-8.78% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
